BCM
COGT icon

Boxer Capital Management’s Cogent Biosciences COGT Stock Holding History

Boxer Capital Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.71M Hold
225,000
– – 0.66% 28
2026
Q1 		$8.66M Hold
225,000
– – 1.14% 24
2025
Q4 		$7.99M Buy
+225,000
New +$6.33M 1.75% 18

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boxer Capital Management's COGT Position: Q2 2026 in Review

Boxer Capital Management held its Cogent Biosciences (COGT) position steady in Q2 2026 at 225,000 shares worth $8.71M. The position accounts for 0.66% of the portfolio, ranked #28.

Boxer Capital Management first reported a position in COGT in Q4 2025 and has held it in 3 quarters since. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Boxer Capital Management held 225,000 shares of Cogent Biosciences worth $8.71M as of Q2 2026.
  • Boxer Capital Management left its Cogent Biosciences share count unchanged in Q2 2026.
  • Cogent Biosciences made up 0.66% of Boxer Capital Management's portfolio in Q2 2026, its #28 holding.
  • Boxer Capital Management first reported a position in Cogent Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Boxer Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.